UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 743

Sortiert nach

Second Malignancies as First Cause of Death in Localized Prostate Cancer Treated With Radiation Therapy: Data from Two Phase 3 Trials

International journal of radiation oncology, biology, physics, 2016-10, Vol.96 (2), p.S185-S185

2016

Volltextzugriff (PDF)

Radiation Therapy With or Without Short-Term Androgen Deprivation Therapy in Intermediate-Risk Prostate Cancer: Results of a Phase 3 Trial

International journal of radiation oncology, biology, physics, 2016, Vol.94 (1), p.4-4

2016

Volltextzugriff (PDF)

Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer

International journal of radiation oncology, biology, physics, 2014-09, Vol.90 (1), p.S15-S16

2014

Volltextzugriff (PDF)

Guideline for testosterone recovery in localized prostate cancer treated with different ADT duration: Long-term data from two prospective randomized trials

European urology open science (Online), 2020-07, Vol.19, p.e250

2020

Volltextzugriff (PDF)

Adherence to Long-term Androgen Blockade in Localized High-Risk Prostate Cancer and Causes of Noncompliance

International journal of radiation oncology, biology, physics, 2012-11, Vol.84 (3), p.S374-S375

2012

Volltextzugriff (PDF)

PO-0668 TESTOSTERONE VARIATION IN INTERMEDIATE RISK PROSTATE CANCER TREATED WITH ANDROGEN BLOCKADE AND RADIOTHERAPY

Radiotherapy and oncology, 2012-05, Vol.103, p.S260-S261

2012

Volltextzugriff (PDF)

Quality of Life and Weight Variation during Androgen Deprivation Therapy in Patients with High-Risk Prostate Cancer: Long-Term Data from a Phase III Trial

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.e566-e567

2024

Volltextzugriff (PDF)

Testosterone Suppression in Patients with Intermediate Risk Prostate Cancer Treated with External Beam Radiotherapy Alone

International journal of radiation oncology, biology, physics, 2011, Vol.81 (2), p.S42-S42

2011

Volltextzugriff (PDF)

Patient Reported Outcomes in High-Risk Prostate Cancer Patients with or without Testosterone Recovery after Androgen Deprivation Therapy

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.S95-S96

2023

Volltextzugriff (PDF)

Biochemical Failure in Intermediate Risk Prostate Cancer: Then What? Long-Term Data from a Phase III Trial

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.e421-e421

2023

Volltextzugriff (PDF)

Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI): Acute Toxicity Results

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.S26-S26

2023

Volltextzugriff (PDF)

Biochemical Recurrence is Not a Surrogate for Overall Survival in Localized Prostate Cancer: Data from 2 Phase III Trials

International journal of radiation oncology, biology, physics, 2024-10, Vol.120 (2), p.e566-e566

2024

Volltextzugriff (PDF)

PO-1544 Outcomes comparison using PSA cut-off values of 0.1 at 6 months in high-risk prostate cancer

Radiotherapy and oncology, 2023-05, Vol.182, p.S1253-S1253

2023

Volltextzugriff (PDF)

Conventional vs. Hypo-Fractionated, Radiotherapy for High-Risk Prostate Cancer (PCS5), Randomized, Non-Inferiority, Phase 3 Trial: Posthoc Analysis of IMRT vs. 3D-CRT Radiation Therapy Associated Toxicities

International journal of radiation oncology, biology, physics, 2023-10, Vol.117 (2), p.S25-S26

2023

Volltextzugriff (PDF)

A0601 - Incidence of cardiovascular death in localized prostate cancer and its relationship to androgen blockade: Long-term data from two phase III trials

European urology, 2024-03, Vol.85, p.S1513-S1513

2024

Volltextzugriff (PDF)

Incidence of cardiovascular death in localized prostate cancer and its relationship to androgen blockade: Long-term data from two phase III trials

European urology, 2024-03, Vol.85, p.S1513

2024

Volltextzugriff (PDF)

Outcomes Based on Risk Factors in Intermediate Risk Prostate Cancer: a Secondary Analysis of a Randomized Phase III Trial

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.S137-S137

2019

Volltextzugriff (PDF)

The Clinical Significance of Bone Mineral Density Changes Following Long Term Androgen Deprivation Therapy in Prostate Cancer Patients Enrolled in the PCS V Trial

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.E312-E313

2019

Volltextzugriff (PDF)

Optimal Hypofractionated Rectal Dose-Volume Constraint From The Prostate Cancer Patients of The PCS V Trial

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.E310-E311

2019

Volltextzugriff (PDF)

Rectal Wall vs. Whole Rectum Dose: Which Volume Better Predicts Gastrointestinal Toxicity from Prostate External Beam Radiotherapy?

International journal of radiation oncology, biology, physics, 2019-09, Vol.105 (1), p.E286-E286

2019

Volltextzugriff (PDF)

P066 - Outcomes after biochemical failure in high risk prostate cancer. Long-term data from a phase III trial

European urology open science (Online), 2023-11, Vol.57, p.S98-S99

2023

Volltextzugriff (PDF)

Outcomes after biochemical failure in high risk prostate cancer. Long-term data from a phase III trial

European urology open science (Online), 2023-11, Vol.57, p.S98-S99

2023

Volltextzugriff (PDF)

Phase 3 Study of Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Adenocarcinoma of the Prostate

International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.S130-S131

2017

Volltextzugriff (PDF)

Significance of Testosterone Suppression in Localized Prostate Cancer Treated with Androgen Deprivation Therapy and Radiotherapy: Data from 2 Phase 3 Trials

International journal of radiation oncology, biology, physics, 2017-10, Vol.99 (2), p.S131-S132

2017

Volltextzugriff (PDF)

Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial

European urology supplements : official journal of the European Association of Urology, 2017-03, Vol.16 (3), p.e96-e97

2017

Volltextzugriff (PDF)

1 – 25 von 743

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(618)
Mit Volltextzugriff
(670)

Publikationsform

3 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(396)
Life Sciences & Biomedicine
(213)
Physical Sciences
(156)
Humans
(128)
Physics
(123)
Animals
(92)
Astronomy & Astrophysics
(82)
Physics, Particles & Fields
(67)
Female
(65)
Biological And Medical Sciences
(63)
Exact Sciences And Technology
(57)
Male
(57)
Physics Of Elementary Particles And Fields
(54)
Technology
(54)
The Physics Of Elementary Particles And Fields
(43)
Nuclear Physics
(40)
Fundamental And Applied Biological Sciences. Psychology
(39)
Physics, Nuclear
(36)
Middle Aged
(35)
Adult
(29)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Second Malignancies as First Cause of Death in Localized Prostate Cancer Treated With Radiation Therapy: Data from Two Phase 3 Trials

Radiation Therapy With or Without Short-Term Androgen Deprivation Therapy in Intermediate-Risk Prostate Cancer: Results of a Phase 3 Trial

Quality of Life in Patients with Testosterone Recovery after Long Term Androgen Deprivation Therapy for High Risk Prostate Cancer

Guideline for testosterone recovery in localized prostate cancer treated with different ADT duration: Long-term data from two prospective randomized trials

Adherence to Long-term Androgen Blockade in Localized High-Risk Prostate Cancer and Causes of Noncompliance

PO-0668 TESTOSTERONE VARIATION IN INTERMEDIATE RISK PROSTATE CANCER TREATED WITH ANDROGEN BLOCKADE AND RADIOTHERAPY

Quality of Life and Weight Variation during Androgen Deprivation Therapy in Patients with High-Risk Prostate Cancer: Long-Term Data from a Phase III Trial

Testosterone Suppression in Patients with Intermediate Risk Prostate Cancer Treated with External Beam Radiotherapy Alone

Patient Reported Outcomes in High-Risk Prostate Cancer Patients with or without Testosterone Recovery after Androgen Deprivation Therapy

Biochemical Failure in Intermediate Risk Prostate Cancer: Then What? Long-Term Data from a Phase III Trial

Phase III Study of Hypofractionated, Dose Escalation Radiotherapy vs. Conventional Pelvic Radiation Therapy followed by High Dose Rate Brachytherapy Boost for High Risk Adenocarcinoma of the Prostate (PCS VI): Acute Toxicity Results

Biochemical Recurrence is Not a Surrogate for Overall Survival in Localized Prostate Cancer: Data from 2 Phase III Trials

PO-1544 Outcomes comparison using PSA cut-off values of 0.1 at 6 months in high-risk prostate cancer

Conventional vs. Hypo-Fractionated, Radiotherapy for High-Risk Prostate Cancer (PCS5), Randomized, Non-Inferiority, Phase 3 Trial: Posthoc Analysis of IMRT vs. 3D-CRT Radiation Therapy Associated Toxicities

A0601 - Incidence of cardiovascular death in localized prostate cancer and its relationship to androgen blockade: Long-term data from two phase III trials

Incidence of cardiovascular death in localized prostate cancer and its relationship to androgen blockade: Long-term data from two phase III trials

Outcomes Based on Risk Factors in Intermediate Risk Prostate Cancer: a Secondary Analysis of a Randomized Phase III Trial

The Clinical Significance of Bone Mineral Density Changes Following Long Term Androgen Deprivation Therapy in Prostate Cancer Patients Enrolled in the PCS V Trial

Optimal Hypofractionated Rectal Dose-Volume Constraint From The Prostate Cancer Patients of The PCS V Trial

Rectal Wall vs. Whole Rectum Dose: Which Volume Better Predicts Gastrointestinal Toxicity from Prostate External Beam Radiotherapy?

P066 - Outcomes after biochemical failure in high risk prostate cancer. Long-term data from a phase III trial

Outcomes after biochemical failure in high risk prostate cancer. Long-term data from a phase III trial

Phase 3 Study of Hypofractionated, Dose Escalation Radiation Therapy for High-Risk Adenocarcinoma of the Prostate

Significance of Testosterone Suppression in Localized Prostate Cancer Treated with Androgen Deprivation Therapy and Radiotherapy: Data from 2 Phase 3 Trials

Does nadir testosterone at the end of long term androgen deprivation therapy predict outcomes in high risk prostate cancer? Data from a phase III trial

Suchergebnisse filtern